Dong-A ST Files for Marketing Approval of Styren Q Tab for Gastritis, Once-Daily Dosing to Enhance Patient Compliance and Market Position
This disclosure pertains to a marketing authorization application with no capital raising or change in share structure; the outstanding shares remain 9,727,819 and market cap is unaffected at approximately 441.6 billion KRW.
Phase 3 trial demonstrated non-inferiority versus the existing Styren tablet with comparable safety, supporting the likelihood of regulatory approval.
No treasury stock acquisition, cancellation, or dividend changes are associated with this event.
Financial soundness indicators such as BIS ratio or NPL were not disclosed in this filing.
[AI Summary]Dong-A ST's filing for Styren Q Tab is a product line extension with no capital market implications; the neutral score of 5 reflects no dilution, routine business development, and minimal governance risk.
KOSPI Filing Information
Investment Decision Related Key Management Matters